Vancomycin 1 GM vials
Ended Awarded Last action
- Contract number
- SPE2D325F344A
- Awardee
-
Hikma Pharmaceuticals USA Inc. UEI NQJ5E87TKNB1 Part of Hikma Specialty USA Inc.
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $237,343
Award facts
- Contract value 100% obligated
- $237,342.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Berkeley Heights, NJ 07922, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $237,342.90 to Hikma Pharmaceuticals USA Inc. (doing business as FKA West-Ward Pharmaceuticals) on August 25, 2025, for the supply of Vancomycin 1 GM vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at Hikma's principal operations facility in Berkeley Heights, New Jersey. No small business set-aside was utilized for this procurement. Hikma Pharmaceuticals USA Inc. is a foreign-owned pharmaceutical manufacturer that serves as a critical supplier of generic injectable medications to the Department of Defense, Department of Veterans Affairs, and other federal healthcare systems.
This delivery order represents a routine pharmaceutical procurement under Hikma's established relationships with federal agencies. Vancomycin is an essential antibiotic widely used in military treatment facilities and Veterans Affairs networks for treating serious bacterial infections. Hikma maintains multiple significant indefinite delivery vehicles with the VA and other federal agencies, including a $216 million Federal Supply Schedule contract and a $38.5 million Blanket Purchase Agreement for pharmaceutical products. The company's extensive track record of delivering critical injectable medications—including vancomycin, doxycycline, naloxone, ketamine, and various intravenous solutions—demonstrates its established capability to support federal healthcare operations and medical readiness requirements across the military and veteran healthcare systems.
Quick answers
Who was awarded contract SPE2D325F344A?
SPE2D325F344A was awarded to Hikma Pharmaceuticals USA Inc. by Medical Supply Chain (Troop Support) on August 25, 2025.
How much is contract SPE2D325F344A worth?
The government has obligated $237,343 on SPE2D325F344A.
Is contract SPE2D325F344A an order under another contract?
Yes. SPE2D325F344A is a delivery order under SPE2D020D0006, an indefinite delivery contract.
Was contract SPE2D325F344A competed?
The extent of competition for SPE2D325F344A was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award